Antibody-drug conjugates are receiving unrivaled attention across the biopharma sector. Fueled by Enhertu’s tumor-agnostic accelerated approval, practice changing combination results from Seagen and ...
Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanced ...
Chart does not reflect overnight price.
Abstract: High-speed wireline data transceivers (TRX) with analog-to-digital converter (ADC) followed by digital signal processor (DSP) on the receiver (RX) equalizer became popular for applications ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback